安罗替尼单药治疗晚期复发性小细胞肺癌的临床效果和安全性  

Clinical Efficacy and Safety of Anlotinib Monotherapy in the Treatment of Advanced Relapsed Small Cell Lung Cancer

作　　者：童斯浩 汪毅[2] 汪超[1] TONG Si-hao;WANG Yi;WANG Chao(Department of Oncology,Chaohu Hospital Affiliated to Anhui Medical University,Chaohu,Anhui 238000,China;Department of Hematology and Oncology,the First People's Hospital of Hefei City,Hefei 230000,China)

机构地区：[1]安徽医科大学附属巢湖医院肿瘤内科,安徽巢湖238000 [2]合肥市第一人民医院血液肿瘤科,合肥230000

出　　处：《临床误诊误治》2022年第8期48-51,56,共5页Clinical Misdiagnosis & Mistherapy

基　　金：安徽省科学技术厅项目(S2020340028)。

摘　　要：目的 评价安罗替尼单药对晚期复发性小细胞肺癌(SCLC)的疗效及安全性。方法 选择2018年8月—2020年8月接受二线化疗后进展的SCLC 40例,根据治疗方法分为观察组和对照组,每组20例。观察组给予安罗替尼治疗,对照组采用最佳支持治疗。比较2组治疗后的客观缓解率(ORR)、疾病控制率(DCR)、无进展生存期(PFS)、总生存期(OS),以及治疗前后Karnofsky功能状态量表(KPS)评分、血清神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、热休克蛋白90α(HSP90α)、血管内皮生长因子(VEGF)和异常糖链糖蛋白(TAP)水平,同时观察药物不良反应情况。结果 观察组DCR明显高于对照组(P<0.05)。2组ORR比较差异无统计学意义(P>0.05)。观察组PFS和OS均明显长于对照组(P<0.05)。治疗后,观察组血清NSE、CEA、HSP90α、VEGF和TAP均明显低于对照组(P<0.05)。治疗前和治疗后,2组KPS评分比较差异均无统计学意义(P>0.05)。治疗后,观察组不良反应均为轻度,给予药物减量和对症治疗后均好转。结论 安罗替尼单药对晚期复发性SCLC临床疗效确切,可在一定程度上改善患者的PFS,不良反应可控。Objective To evaluate the efficacy and safety of Anlotinib monotherapy in patients with advanced recurrent small cell lung cancer(SCLC).Methods A total of 40 cases of SCLC who progressed after receiving second-line chemotherapy from August 2018 to August 2020 were selected and divided into observation group(n=20)and control group(n=20)according to the treatment method.The observation group was given Anlotinib,and the control group was given the optimal supportive care.The objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS),overall survival(OS),Karnofsky functional status scale(KPS)score,and the levels of serum neuron-specific enolase(NSE),carcinoembryonic antigen(CEA),heat shock protein 90α(HSP90α),vascular endothelial growth factor(VEGF)and tumor abnormal protein(TAP)in the two groups were compared after treatment,and adverse drug reactions were observed.Results The DCR in the observation group was significantly higher than that in the control group(P<0.05).There was no significant difference in ORR between the two groups(P>0.05).The PFS and OS of the observation group were significantly longer than those of the control group(P<0.05).After treatment,serum NSE,CEA,HSP90α,VEGF and TAP in the observation group were significantly lower than those in the control group(P<0.05).Before and after treatment,there was no significant difference in KPS score between the two groups(P>0.05).After treatment,the adverse reactions in the observation group were all mild,and the patients were all improved after drug reduction and symptomatic treatment.Conclusion Anlotinib has definite clinical efficacy in the treatment of advanced recurrent SCLC,and can improve the PFS of patients to a certain extent,and the adverse reactions are controllable.

关 键 词：小细胞肺癌 安罗替尼 神经元特异性烯醇化酶 癌胚抗原 血管内皮生长因子 预后 

分 类 号：R734.2[医药卫生—肿瘤]